The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters it would be in line with other recently launched ALS treatments and out-of-pocket costs ...

If approved, tofersen would be the first treatment to target a genetic cause of ALS, albeit one ... by 25 January, and Biogen will also have to make the case for its drug at an advisory committee ...

Biogen hasn’t let a phase 3 failure for tofersen ... for a new drug application of the amyotrophic lateral sclerosis (ALS) drug. If approved, the Ionis Pharmaceuticals-partnered prospect would ...

Biogen’s CEO may have been celebrating ... That includes the amyotrophic lateral sclerosis (ALS) drug BIIB105, which was designed to reduce expression of the ATXN2 gene.

Due to increased competitive pressure, sales of the Biogen drug have declined almost ... patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS). Qalsody was also approved ...

Alzheimer’s disease, Parkinson’s disease and ALS are some of the toughest problems in medicine. Biogen Inc. wants to make drugs for all of them. It’s an ambitious goal that could produce med ...

Biogen's results beat estimates on strength ... January 6, 2025 Denali Therapeutics' ALS drug fails in mid-to-late stage trial Denali Therapeutics said on Monday its experimental drug failed ...

(Reuters) - Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis medicines.